Aileron Therapeutics Files 8-K
Ticker: RNTX · Form: 8-K · Filed: Aug 21, 2024 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Aileron Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | Aug 21, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing, financials
TL;DR
Aileron Therapeutics filed an 8-K on Aug 20, 2024, covering shareholder votes and financials.
AI Summary
Aileron Therapeutics, Inc. filed an 8-K on August 21, 2024, reporting on matters submitted to a vote of security holders and financial statements/exhibits. The filing pertains to events on August 20, 2024, with the company's principal executive offices located in Austin, Texas.
Why It Matters
This filing indicates corporate actions and financial reporting by Aileron Therapeutics, Inc., which could impact investors' understanding of the company's status and governance.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain immediate negative news or significant financial events.
Key Players & Entities
- Aileron Therapeutics, Inc. (company) — Registrant
- August 20, 2024 (date) — Earliest event reported
- August 21, 2024 (date) — Date of report
- Austin, Texas (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in the excerpt.
What financial statements and exhibits are included in this filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific content of these statements and exhibits is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on August 20, 2024.
Where are Aileron Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 12407 N. Mopac Expy., Suite 250 #390, Austin, Texas 78758.
What is the SEC file number for Aileron Therapeutics, Inc.?
The SEC file number is 001-38130.
Filing Stats: 579 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-08-21 16:17:00
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ALRN The Nasdaq
Filing Documents
- d862681d8k.htm (8-K) — 33KB
- 0001193125-24-204425.txt ( ) — 155KB
- alrn-20240820.xsd (EX-101.SCH) — 3KB
- alrn-20240820_lab.xml (EX-101.LAB) — 18KB
- alrn-20240820_pre.xml (EX-101.PRE) — 11KB
- d862681d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AILERON THERAPEUTICS, INC. Date: August 21, 2024 By: /s/ Brian Windsor Brian Windsor, Ph.D. President and Chief Executive Officer